Valerion Therapeutics is a biotechnology company focused on developing targeted therapies for orphan genetic diseases

Valerion Therapeutics is utilizing a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a well-known and broadly studied transport pathway.

This platform is capable of enhanced intracellular delivery of a variety of active therapeutic payloads via a transport mechanism that is present in muscle and neurons and elevated in certain types of cancer.

Pipeline candidates include therapeutic agents aimed at addressing a host of orphan genetic disorders with limited or no current therapies.